GlassScriptPhysician profile
Ronald K Jorgensen
NPI 1760473466
$18,597.37
in general payments reported to CMS, 2019-2025
46 companies · $2,823 in 2025
The $2,823 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,982 · 2020: $1,455 · 2021: $2,578 · 2022: $2,671 · 2023: $2,350 · 2024: $2,738 · 2025: $2,823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,680 · Consulting Fee: $135 · Education: $95.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,680.46 |
| Consulting Fee | $134.61 |
| Education | $95.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,266.79 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,937.07 | 2019-2023 | Spiriva Respimat |
| Astrazeneca Pharmaceuticals LP | $1,738.58 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Kaleo, INC. | $1,365.81 | 2019-2024 | Auvi-Q |
| Genzyme Corporation | $948.99 | 2019-2025 | |
| Genentech USA, INC. | $913.40 | 2019-2025 | Xolair |
| Regeneron Healthcare Solutions, INC. | $903.27 | 2019-2025 | Dupixent |
| Optinose US, INC. | $870.24 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $848.16 | 2020-2025 | Cuvitru, Eohilia, Takhzyro |
| Pfizer INC. | $786.43 | 2019-2025 | |
| Csl Behring | $738.65 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Blueprint Medicines Corporation | $680.86 | 2021-2025 | Ayvakit |
| Novartis Pharmaceuticals Corporation | $661.18 | 2019-2025 | |
| Grifols USA, LLC | $469.61 | 2019-2025 | Xembify |
| Amgen INC. | $394.69 | 2021-2025 | Tezspire, Actimmune |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $364.32 | 2021-2023 | |
| Pharming Healthcare, INC. | $327.44 | 2019-2025 | Ruconest |
| Octapharma USA, INC. | $260.98 | 2019-2025 | Panzyga, Octagam Immune Globulin (Human) |
| Teva Pharmaceuticals USA, INC. | $209.56 | 2019-2023 | Airduo Digihaler |
| Shire North American Group INC | $189.38 | 2019 | |
| Covis Pharma Gmbh | $175.32 | 2021-2022 | |
| Incyte Corporation | $159.87 | 2021-2025 | Opzelura |
| Adma Biomanufacturing LLC | $145.60 | 2022-2025 | |
| Genentech, INC. | $131.76 | 2019 | |
| Kedrion Biopharma, INC. | $118.75 | 2023-2025 | Rhogam Ultra-Filtered Plus, Albuked, Gammaked |
| Gc Biopharma USA, INC. | $102.57 | 2025 | Alyglo |
| Leo Pharma INC. | $99.92 | 2022-2023 | Adbry |
| Tersera Therapeutics LLC | $77.88 | 2024-2025 | Quzyttir |
| Galderma Laboratories, L.P. | $67.86 | 2024-2025 | Nemluvio |
| Organon LLC | $64.52 | 2025 | Vtama |
| Biocryst US Sales Co., LLC | $62.35 | 2021-2024 | Orladeyo |
| Phadia US INC. | $62.12 | 2020-2024 | Immunocap |
| Baxter Healthcare | $54.09 | 2022-2023 | Hillrom - Vest System Model 105 Home Care |
| Ars Pharmaceuticals Operations, INC. | $49.74 | 2025 | Neffy |
| Lilly USA, LLC | $48.38 | 2024-2025 | Ebglyss |
| Sunovion Pharmaceuticals INC. | $46.31 | 2019-2020 | |
| Advanced Respiratory, INC | $37.18 | 2019-2021 | |
| Horizon Therapeutics Plc | $32.83 | 2019-2020 | |
| Arcutis Biotherapeutics, INC. | $31.89 | 2025 | Zoryve |
| Bio Products Laboratory USA, INC. | $28.73 | 2022-2023 | Coagadex, Gammaplex |
| Merck Sharp & Dohme LLC | $28.31 | 2019-2021 | |
| Electromed, INC. | $26.35 | 2021 | |
| Inspire Medical Systems, INC. | $23.85 | 2024 | Inspire |
| Seqirus USA INC | $16.37 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Dermavant Sciences, INC. | $16.20 | 2024 | Vtama |
| Circassia INC. | $13.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Jorgensen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.